GlassScriptPhysician profile
Molly Jenner
NPI 1174029276
$3,228.82
in general payments reported to CMS, 2019-2025
28 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $272 · 2023: $753 · 2024: $834 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699 · Consulting Fee: $1,000 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.54 |
| Consulting Fee | $1,000.00 |
| Education | $257.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,000.00 | 2025 | |
| Sumitomo Pharma America, INC. | $338.03 | 2023-2025 | Myfembree |
| Organon LLC | $280.93 | 2022-2025 | Nexplanon |
| Fisher Scientific Company L.L.C. | $257.90 | 2024 | Procalcitonin |
| Astellas Pharma US INC | $165.76 | 2023-2024 | Veozah, Myrbetriq |
| Sage Therapeutics, LLC | $150.93 | 2022-2025 | Zurzuvae |
| Exeltis, USA INC. | $147.05 | 2022-2025 | Slynd |
| Abbvie INC. | $146.91 | 2023 | |
| Mayne Pharma Commercial LLC | $119.61 | 2022-2025 | |
| Pfizer INC. | $104.30 | 2023-2025 | |
| Myovant Sciences INC. | $70.11 | 2022 | |
| Millicent US INC | $59.15 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Myriad Women'S Health, INC. | $50.19 | 2023 | Myrisk |
| Avion Pharmaceuticals | $48.21 | 2022-2023 | Balcoltra |
| Bayer Healthcare Pharmaceuticals INC. | $27.73 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $27.23 | 2025 | |
| Axonics, INC. | $24.16 | 2023 | Bulkamid |
| Caldera Medical, INC | $23.76 | 2025 | |
| Shield Therapeutics INC | $23.38 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $22.68 | 2024 | Gardasil, Gardasil 9 |
| Davol INC. | $21.47 | 2022 | |
| Therapeuticsmd, INC. | $20.09 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.87 | 2025 | Qelbree |
| Medtronic, INC. | $17.85 | 2025 | Ligasure |
| Teleflex LLC | $16.42 | 2025 | Quikclot |
| Integra Lifesciences Corporation | $15.66 | 2024 | Biodrestore, Medihoney, Biodfactor |
| Becton, Dickinson and Company | $15.33 | 2022 | |
| Agile Therapeutics, INC. | $15.11 | 2023 | Twirla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Jenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.